Similarly, the better neurological outcome reported afteradministration of PPAR-γ ligands in experimental stroke models are consistent with the result of a smallclinical trial reporting that patients with diabetes receiving pioglitazone orrosiglitazone had an improved functional recovery after stroke compare topatients, who have not used any TZD [93]. The gene discussed is PPARG; the disease is diabetes mellitus.